Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20945384 | 0.84 | ALDH1A1 (0.56) | ALDH1A1FFAR1MAOBPTPN1MAOA | |
| SCHEMBL2659356 | 0.84 | ALDH1A1 (0.56) | ALDH1A1CYP3A4IDH1FFAR1MAOB | |
| SCHEMBL18641314 | 0.84 | LMNA (0.42) | FFAR1MAOBPTPN1LMNAFFAR4 | |
| SCHEMBL6709375 | 0.82 | ALDH1A1 (0.73) | ALDH1A1CYP3A4IDH1MIFMAOB | |
| SCHEMBL43788 | 0.80 | ALDH1A1 (0.58) | ALDH1A1CYP3A4IDH1MAOBCA2 | |
| SCHEMBL3346401 | 0.79 | ALDH1A1 (0.50) | ALDH1A1CYP3A4IDH1FFAR1MIF | |
| SCHEMBL19369942 | 0.78 | FFAR1 (0.44) | ALDH1A1FFAR1PTPN1LMNACA2 | |
| SCHEMBL2385123 | 0.78 | ALDH1A1 (0.66) | ALDH1A1CYP3A4IDH1 | |
| SCHEMBL801397 | 0.76 | ALDH1A1 (0.63) | ALDH1A1CYP3A4IDH1FFAR1MIF | |
| SCHEMBL7671543 | 0.76 | ALDH1A1 (0.63) | ALDH1A1CYP3A4IDH1MIFPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1759118-B | Diazepinoindole derivatives as kinase inhibitors | PFIZER | 2010-12-08 | — | — | CN | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1585749-B1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1947102-A1 | Compositions comprising diazepinoindole derivatives as kinase inhibitors | Pfizer, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1947102-A1 | Compositions comprising diazepinoindole derivatives as kinase inhibitors | Pfizer, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7132533-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| CN-1759118-A | Diazepinoindole derivatives as kinase inhibitors | PFIZER (US) | 2006-04-12 | — | — | CN | disclosed |
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-6967198-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS INC. (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1585749-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2004063198-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK1, CHEK2, CHKA | ALDH1A1 4205/4885CYP3A4 3688/4885IDH1 1609/4885 |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | ALDH1A1 4319/4885CYP3A4 3815/4885IDH1 1853/4885 |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | ALDH1A1 4198/4885CYP3A4 3724/4885IDH1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.